See more : AddLife AB (publ) (ALIF-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectar Biosciences, Inc. (CLRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectar Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pragma Inkaso S.A. (PRI.WA) Income Statement Analysis – Financial Results
- Kohl’s Corporation (0JRL.L) Income Statement Analysis – Financial Results
- Arezzo Indústria e Comércio S.A. (ARZZ3.SA) Income Statement Analysis – Financial Results
- Foods & Inns Ltd (FOODSIN.BO) Income Statement Analysis – Financial Results
- Jiugui Liquor Co., Ltd. (000799.SZ) Income Statement Analysis – Financial Results
Cellectar Biosciences, Inc. (CLRB)
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 4.96K |
| Cost of Revenue | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Gross Profit | -192.38K | -238.87K | -227.64K | -207.93K | -189.36K | -82.27K | -1.55M | -356.67K | -362.50K | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 2.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 48.85% |
| Research & Development | 27.27M | 19.22M | 17.59M | 10.14M | 9.00M | 6.84M | 9.47M | 4.75M | 5.16M | 5.96M | 6.86M | 5.12M | 3.60M | 3.00M | 8.08M | 14.53M | 17.43M | 6.44M | 1.14M | 261.77K |
| General & Administrative | 10.75M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 0.00 | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 0.00 | 0.00 |
| Selling & Marketing | 945.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.69M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 2.69M | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 1.44M | 365.88K |
| Other Expenses | 0.00 | 0.00 | 6.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 627.64K |
| Cost & Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 630.18K |
| Interest Income | 0.00 | 152.52K | 2.28K | 10.90K | 42.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.50K | 2.42K | 1.01K | 130.61K | 729.92K | 637.75K | 49.88K | 95.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.69K | 16.61K | 7.90K | 841.00 | 446.31K | 9.35K | 9.34K | 430.02K | 2.42K | 1.01K | 130.61K | 0.00 | 0.00 | 0.00 | 208.74K |
| Depreciation & Amortization | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 367.20K | 424.76K | 497.25K | 584.84K | 35.34K | 32.35K | 16.89K | 15.37K | 9.52K | 3.24K | 2.54K |
| EBITDA | -38.77M | -28.67M | -23.98M | -15.15M | -13.90M | -13.16M | -12.05M | -9.09M | -8.19M | -9.30M | -10.88M | -8.29M | -6.33M | -12.96M | -10.17M | -16.59M | -19.54M | -8.28M | -2.94M | -604.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45,388.96% | -38,876.20% | 2,049.87% | -13,164.56% | 0.00% | 0.00% | -16,968.75% | -12,172.63% |
| Operating Income | -38.96M | -28.81M | -24.13M | -15.29M | -14.18M | -13.33M | -13.60M | -9.45M | -8.76M | -9.89M | -12.40M | -8.75M | -7.04M | -5.45M | -10.17M | -16.59M | -20.29M | -8.93M | -5.09M | -625.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63,979.27% | -16,351.72% | -10,555.25% | -13,170.82% | 0.00% | 0.00% | -40,428.32% | -12,600.14% |
| Total Other Income/Expenses | 917.15K | 152.52K | 8.92K | 196.18K | 85.71K | 91.74K | 38.68K | 3.27M | 3.26M | 1.78M | 522.76K | -42.19K | -1.89M | -7.20M | -12.11M | 139.61K | 737.05K | 382.63K | -487.02K | -190.07K |
| Income Before Tax | -38.04M | -28.66M | -24.12M | -15.09M | -14.09M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.75M | -12.65M | -26.28M | -22.96M | -29.72M | -8.55M | -3.16M | -815.29K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,469.15% | -37,960.15% | -27,289.52% | -18,227.50% | 0.00% | 0.00% | -25,146.86% | -16,430.57% |
| Income Tax Expense | -60.00K | -60.00K | -152.20K | -337.63K | -218.51K | -1.55M | -38.68K | -3.27M | -3.42M | -1.56M | -522.76K | 9.34K | 1.14M | -7.55M | 12.11M | -139.61K | -737.05K | -643.75K | 487.02K | 0.00 |
| Net Income | -37.98M | -28.60M | -23.97M | -14.76M | -13.87M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.44M | 2.10M | -22.27M | -16.45M | -19.56M | -8.29M | -3.05M | -815.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 67,594.75% | 6,286.05% | -23,125.72% | -13,059.99% | 0.00% | 0.00% | -24,264.14% | -16,430.57% |
| EPS | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| EPS Diluted | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| Weighted Avg Shares Out | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
| Weighted Avg Shares Out (Dil) | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Tranche A warrants...
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient
Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in...
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.
Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the...
Cellectar's blood cancer therapy succeeds in trial
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia
FLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced data from its CLOVER WaM...
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads
Source: https://incomestatements.info
Category: Stock Reports